SAN
JOSE, Calif., July 17,
2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced that its
collaborator, Cleveland Clinic, has received a "Decision to Grant"
notice from the Japan Patent Office (JPO) for the patent
application titled "Vaccine Adjuvants and Formulations."
"This new Japanese patent extends the claims for this novel
breast cancer vaccine technology to an additional geographic
region, beyond the U.S. and European patents previously awarded,"
stated Anixa Chairman and CEO Dr. Amit
Kumar. "As the exclusive worldwide licensee of the
technology, we value the additional protection this patent provides
as we continue clinical development."
The vaccine is currently being studied in a phase one clinical
trial at Cleveland Clinic.
Anixa's breast cancer vaccine takes advantage of endogenously
produced proteins that have a function at certain times in life,
but then become "retired" and disappear from the body. One such
protein is a breast-specific lactation protein, α-lactalbumin,
which is no longer found post-lactation in normal, aging tissues,
but is present in certain breast cancers. Activating the immune
system against this "retired" protein provides preemptive immune
protection against emerging breast tumors that express
α-lactalbumin. The vaccine also contains an adjuvant that activates
an innate immune response, which allows the immune system to mount
a response against emerging tumors to prevent them from
growing.
This vaccine technology was invented by the late Dr.
Vincent Tuohy, who was the Mort and
Iris November Distinguished Chair in Innovative Breast Cancer
Research in the Department of Inflammation and Immunity at
Cleveland Clinic's Lerner Research Institute. Cleveland Clinic
exclusively licensed this technology to Anixa Biosciences. Dr.
Tuohy was entitled to a portion of the commercialization revenues
received by Cleveland Clinic and also held equity in Anixa.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to prevent breast
cancer – specifically triple negative breast cancer (TNBC), the
most lethal form of the disease – and ovarian cancer, as well as
additional cancer vaccines to address many intractable cancers,
including high incidence malignancies in lung, colon, and prostate.
These vaccine technologies focus on immunizing against "retired"
proteins that have been found to be expressed in certain forms of
cancer. Anixa's unique business model of partnering with
world-renowned research institutions on all stages of development
allows the Company to continually examine emerging technologies in
complementary fields for further development and commercialization.
To learn more, visit www.anixa.com or follow Anixa on Twitter,
LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-japanese-patent-on-breast-cancer-vaccine-technology-302198777.html
SOURCE Anixa Biosciences, Inc.